Rheumatoid arthritis

Hope Biosciences Receives Second FDA Clearance for a Phase II Clinical Trial for Protection Against COVID-19

Monday, April 13, 2020 - 1:00pm

In a recent Phase I/II clinical trial for Rheumatoid Arthritis, results appeared to show that HB-adMSCs were safe and effective in attenuating systemic inflammation.

Key Points: 
  • In a recent Phase I/II clinical trial for Rheumatoid Arthritis, results appeared to show that HB-adMSCs were safe and effective in attenuating systemic inflammation.
  • With this treatment, we hope to build a line of defense for our most vulnerable, said Donna Chang, President and CEO of Hope Biosciences.
  • This is the second of three New Drug Applications (INDs), related to COVID-19, that Hope Biosciences has filed with FDA.
  • Hope Biosciences is a clinical stage biotechnology company focused on developing novel cell-based therapeutics for acute and chronic injury and disease.

Alopecia Industry Growth Opportunities, 2020-2027 - Increasing Prevalence of Diseases Across the Globe, Technological Progression, Growth in Per-Capita Expenditures Toward Healthcare

Thursday, April 9, 2020 - 3:45pm

Increasing prevalence of diseases across the globe, technological progress, and growth in per-capita expenditures toward healthcare are some of the factors expected to drive the market growth in the coming years.

Key Points: 
  • Increasing prevalence of diseases across the globe, technological progress, and growth in per-capita expenditures toward healthcare are some of the factors expected to drive the market growth in the coming years.
  • In addition, rising incidences of chronic diseases such as rheumatoid arthritis, cancer, and Polycystic Ovary Syndrome (PCOS) are anticipated to fuel the market growth.
  • The National Alopecia Areata Foundation stated that 147 million people are suffering from alopecia areata worldwide.
  • Expanding consumer awareness towards this disease and possible treatments options are expected to augment the alopecia market growth.

Alopecia Industry Growth Opportunities, 2020-2027 - Increasing Prevalence of Diseases Across the Globe, Technological Progression, Growth in Per-Capita Expenditures Toward Healthcare

Wednesday, April 8, 2020 - 3:15pm

Increasing prevalence of diseases across the globe, technological progress, and growth in per-capita expenditures toward healthcare are some of the factors expected to drive the market growth in the coming years.

Key Points: 
  • Increasing prevalence of diseases across the globe, technological progress, and growth in per-capita expenditures toward healthcare are some of the factors expected to drive the market growth in the coming years.
  • In addition, rising incidences of chronic diseases such as rheumatoid arthritis, cancer, and Polycystic Ovary Syndrome (PCOS) are anticipated to fuel the market growth.
  • The National Alopecia Areata Foundation stated that 147 million people are suffering from alopecia areata worldwide.
  • Expanding consumer awareness towards this disease and possible treatments options are expected to augment the alopecia market growth.

Hope Biosciences Receives FDA Approval to Commence First Stem Cell Clinical Trial for Protection Against COVID-19

Monday, April 6, 2020 - 5:08pm

In a recent Phase I/II clinical trial for Rheumatoid Arthritis, results appeared to show that HB-adMSCs were safe and effective in attenuating systemic inflammation.

Key Points: 
  • In a recent Phase I/II clinical trial for Rheumatoid Arthritis, results appeared to show that HB-adMSCs were safe and effective in attenuating systemic inflammation.
  • This study will utilize our proprietary core technology to deliver high quality, pure mesenchymal stem cells with standardized doses and multiple treatments.
  • This is the first of three New Drug Applications (INDs), related to COVID-19, that Hope Biosciences has filed with FDA.
  • This initial protocol is specifically designed for patients who already have their own stem cells banked with Hope Biosciences.

DocTalkGo Provides At-Home Coronavirus (COVID-19) Screening and FDA Approved Hydroxychloroquine

Wednesday, April 1, 2020 - 6:00am

If you are experiencing symptoms, visit https://www.covidmedicaltest.com/ for an immediate, same-day coronavirus screening and FREE home delivery of FDA approved hydroxychloroquine within just three (3) days.

Key Points: 
  • If you are experiencing symptoms, visit https://www.covidmedicaltest.com/ for an immediate, same-day coronavirus screening and FREE home delivery of FDA approved hydroxychloroquine within just three (3) days.
  • Hydroxychloroquine (which can only be prescribed after a positive COVID-19 test), is also used to treat malaria, lupus and rheumatoid arthritis is expected to reduce coronavirus symptoms within six days.
  • If approved, prescriptions will be delivered to your home via 2-day or overnight mail, along with any additional symptom relieving prescriptions approved by one of our doctors.
  • The use of hydroxychloroquine in preliminary studies have shown very encouraging results in treating the coronavirus.

I-Mab Submits IND Application to Initiate Study of TJM2 for Treatment of Cytokine Storm Associated with Severe COVID-19 in South Korea

Monday, March 30, 2020 - 1:25pm

The IND submission follows the announcement on March 13, 2020 of a similar program initiated by I-Mab in the U.S.

Key Points: 
  • The IND submission follows the announcement on March 13, 2020 of a similar program initiated by I-Mab in the U.S.
  • The proposed clinical trial in South Korea is a single-arm, open-label pilot study that will evaluate the effects of TJM2 on reducing cytokine levels, including GM-CSF, in patients with severe COVID-19 disease.
  • The Company has successfully completed a Phase I single ascending dose study of TJM2 in the United States (NCT03794180), in which TJM2 exhibited favorable safety, tolerability, PK/PD, and immunogenicity profiles.
  • TJM2 also received IND clearance from Chinas National Medical Products Administration for a multiple-dose Phase 1b study in patients with rheumatoid arthritis (RA).

New Research Among People Living With Rheumatoid Arthritis Reveals Key Determinants Of Patient Satisfaction With Doctors

Friday, March 20, 2020 - 4:57pm

Key findings spanned topics including patient satisfaction with their doctors, the impact RA has on quality of life, and common symptoms and flare-up triggers.

Key Points: 
  • Key findings spanned topics including patient satisfaction with their doctors, the impact RA has on quality of life, and common symptoms and flare-up triggers.
  • "Joint pain is just the tip of the iceberg for those living with rheumatoid arthritis.
  • You've got to treat the whole person, not just their obvious symptoms," said Eric Peacock, cofounder and CEO of MyHealthTeams.
  • There is a high correlation between treatment satisfaction and doctor satisfaction, so if treatment isn't working to control a patient's RA, it's unlikely she will be satisfied with her doctor.

Can-Fite to Participate in Digital Bio-Europe Spring Partnering Conference; Looks to Partner on Co-Development of Piclidenoson for Coronavirus Treatment

Wednesday, March 18, 2020 - 11:00am

Piclidenoson, currently in Phase III clinical studies for the treatment of rheumatoid arthritis, has begun pre-clinical testing for the treatment of coronavirus.

Key Points: 
  • Piclidenoson, currently in Phase III clinical studies for the treatment of rheumatoid arthritis, has begun pre-clinical testing for the treatment of coronavirus.
  • Piclidenoson is an anti-rheumatic drug with positive efficacy signals in Phase II clinical studies and currently in Phase III.
  • Today, drugs with this profile are under clinical studies for the treatment of coronavirus to combat the uncontrolled immune response created by the disease.
  • In conjunction with Temple Universitys Lewis Katz School of Medicine in Philadelphia, Can-Fite is currently testing Piclidenosons anti-viral effects against coronavirus.

Visiongain Report: Global Rheumatoid Arthritis Drugs Market Estimated to Grow at a CAGR of 0.6% in the Second Half of the Forecast Period

Wednesday, March 18, 2020 - 10:00am

What is driving and restraining the Rheumatoid Arthritis drugs market?

Key Points: 
  • What is driving and restraining the Rheumatoid Arthritis drugs market?
  • What are the market shares of each segment of the overall Rheumatoid Arthritis drugs market in 2018?
  • How will each Rheumatoid Arthritis drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2030?
  • How will the market shares for each Rheumatoid Arthritis drugs submarket develop from 2020 to 2030?

Visiongain Report: Global Rheumatoid Arthritis Drugs Market Estimated to Grow at a CAGR of 0.6% in the Second Half of the Forecast Period

Wednesday, March 18, 2020 - 10:00am

What is driving and restraining the Rheumatoid Arthritis drugs market?

Key Points: 
  • What is driving and restraining the Rheumatoid Arthritis drugs market?
  • What are the market shares of each segment of the overall Rheumatoid Arthritis drugs market in 2018?
  • How will each Rheumatoid Arthritis drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2030?
  • How will the market shares for each Rheumatoid Arthritis drugs submarket develop from 2020 to 2030?